生物制剂在银屑病和特应性皮炎中的应用与免疫表型转换机制研究进展

doi:10.35541/cjd.20220795

中华皮肤科杂志 ›› 2024, e20220795.doi: 10.35541/cjd.20220795

生物制剂在银屑病和特应性皮炎中的应用与免疫表型转换机制研究进展

叶慧薛如君张锡宝

广州医科大学皮肤病研究所广州市皮肤病医院，广州 510095

收稿日期:2022-11-10 修回日期:2023-06-08 发布日期:2024-05-08
通讯作者: 张锡宝 E-mail:zxibao@126.com
基金资助:
广州市科技计划项目2023年度市校（院）企联合资助项目（2023A03J0944）

Application of biological therapies and mechanisms of immunophenotypic switching in psoriasis and atopic dermatitis

Ye Hui, Xue Rujun, Zhang Xibao

Institute of Dermatology, Guangzhou Medical University, Guangzhou Dermatology Hospital, Guangzhou 510095, China

Received:2022-11-10 Revised:2023-06-08 Published:2024-05-08
Contact: Zhang Xibao E-mail:zxibao@126.com
Supported by:
Science and Technology Program of Guangzhou（2023A03J0944）

摘要/Abstract

摘要： 【摘要】生物制剂已成功用于银屑病和特应性皮炎的治疗，一些独特的免疫表型转换现象也不断出现。本文综述了生物制剂治疗银屑病和特应性皮炎过程中患者发生免疫表型转换现象的现状和机制研究，以更全面深入地认识和了解这种新的异常免疫反应。

关键词: 银屑病, 皮炎, 特应性, 生物制剂, 湿疹, 免疫表型转换

Abstract: 【Abstract】 While biologic therapies have been successfully applied in the treatment of psoriasis and atopic dermatitis, unique phenomena of immunophenotypic switching have also been constantly reported. This review summarizes the current status and mechanisms of immunophenotypic switching among patients with psoriasis or atopic dermatitis during the treatment with biologic therapies, in order to fully understand this new abnormal immune reaction.

Key words: Psoriasis, Dermatitis, atopic, Biological agents, Eczema, Immunophenotypic switching

叶慧薛如君张锡宝. 生物制剂在银屑病和特应性皮炎中的应用与免疫表型转换机制研究进展[J]. 中华皮肤科杂志, 2024,e20220795. doi:10.35541/cjd.20220795

Ye Hui, Xue Rujun, Zhang Xibao. Application of biological therapies and mechanisms of immunophenotypic switching in psoriasis and atopic dermatitis[J]. Chinese Journal of Dermatology,2024,e20220795. doi:10.35541/cjd.20220795

参考文献 45

［1］	Caldarola G, Pirro F, Di Stefani A, et al. Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL⁃17 treatment: a case series and review of the literature［J］. Expert Opin Biol Ther, 2020,20（6）:665⁃672. doi: 10.1080/14712598.2020.1727439.
［2］	Al⁃Janabi A, Foulkes AC, Mason K, et al. Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review［J］. J Eur Acad Dermatol Venereol, 2020,34（7）:1440⁃1448. doi: 10.1111/jdv.16246.
［3］	Davaine AC, Saraux A, Prigent S, et al. Cutaneous events during treatment of chronic inflammatory joint disorders with anti⁃tumour necrosis factor alpha: a cross⁃sectional study［J］. J Eur Acad Dermatol Venereol, 2008,22（12）:1471⁃1477. doi: 10.1111/j.1468⁃3083.2008.02935.x.
［4］	Napolitano M, Scalvenzi M, Fabbrocini G, et al. Occurrence of psoriasiform eruption during dupilumab therapy for adult atopic dermatitis: a case series［J］. Dermatol Ther, 2019,32（6）:e13142. doi: 10.1111/dth.13142.
［5］	Jaulent L, Staumont⁃Sallé D, Tauber M, et al. De novo psoriasis in atopic dermatitis patients treated with dupilumab: a retrospective cohort［J］. J Eur Acad Dermatol Venereol, 2021,35（4）:e296⁃296e297. doi: 10.1111/jdv.17050.
［6］	Flanagan KE, Pupo Wiss IM, Pathoulas JT, et al. Dupilumab⁃induced psoriasis in a patient with atopic dermatitis and alopecia totalis: a case report and literature review［J］. Dermatol Ther, 2022,35（2）:e15255. doi: 10.1111/dth.15255.
［7］	Tracey EH, Elston C, Feasel P, et al. Erythrodermic presentation of psoriasis in a patient treated with dupilumab［J］. JAAD Case Rep, 2018,4（7）:708⁃710. doi: 10.1016/j.jdcr.2018.05.014.
［8］	Czarnowicki T, He H, Krueger JG, et al. Atopic dermatitis endotypes and implications for targeted therapeutics［J］. J Allergy Clin Immunol, 2019,143（1）:1⁃11. doi: 10.1016/j.jaci. 2018.10.032.
［9］	Dai YX, Tai YH, Chang YT, et al. Bidirectional association between psoriasis and atopic dermatitis: a nationwide population⁃based cohort study［J］. Dermatology, 2021,237（4）:521⁃527. doi: 10.1159/000514581.
［10］	Chen WY, Chen SC, Hsu SY, et al. Annoying psoriasis and atopic dermatitis: a narrative review［J］. Int J Mol Sci, 2022,23（9）:4898. doi: 10.3390/ijms23094898.
［11］	Langan SM, Irvine AD, Weidinger S. Atopic dermatitis［J］. Lancet, 2020,396（10247）:345⁃360. doi: 10.1016/S0140⁃6736（20）31286⁃1.
［12］	Yang G, Seok JK, Kang HC, et al. Skin barrier abnormalities and immune dysfunction in atopic dermatitis［J］. Int J Mol Sci, 2020,21（8）:2867. doi: 10.3390/ijms21082867.
［13］	Tsai YC, Tsai TF. Overlapping features of psoriasis and atopic dermatitis: from genetics to immunopathogenesis to phenotypes［J］. Int J Mol Sci, 2022,23（10）:5518. doi: 10.3390/ijms23105518.
［14］	Newsom M, Bashyam AM, Balogh EA, et al. New and emerging systemic treatments for atopic dermatitis［J］. Drugs, 2020,80（11）:1041⁃1052. doi: 10.1007/s40265⁃020⁃01335⁃7.
［15］	de Alcantara CC, Reiche E, Simão A. Cytokines in psoriasis［J］. Adv Clin Chem, 2021,100:171⁃204. doi: 10.1016/bs.acc.2020. 04.004.
［16］	Safa G, Paumier V. Psoriasis induced by dupilumab therapy［J］. Clin Exp Dermatol, 2019,44（3）:e49⁃e50. doi: 10.1111/ced. 13901.
［17］	Zaba LC, Cardinale I, Gilleaudeau P, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses［J］. J Exp Med, 2007,204（13）:3183⁃3194. doi: 10.1084/jem.20071094.
［18］	Al⁃Janabi A, Foulkes AC, Griffiths C, et al. Paradoxical eczema in patients with psoriasis receiving biologics: a case series［J］. Clin Exp Dermatol, 2022,47（6）:1174⁃1178. doi: 10.1111/ced. 15130.
［19］	Dumont⁃Berset M, Laffitte E, Gerber C, et al. Eczematous drug eruption after infliximab［J］. Br J Dermatol, 2004,151（6）:1272⁃1273. doi: 10.1111/j.1365⁃2133.2004.06282.x.
［20］	Senner S, Eicher L, Aszodi N, et al. Psoriasis in dupilumab⁃treated atopic dermatitis［J］. Hautarzt, 2020,71（5）:383⁃386. doi: 10.1007/s00105⁃020⁃04565⁃8.
［21］	Pouillot A, Dayan N, Polla AS, et al. The stratum corneum: a double paradox［J］. J Cosmet Dermatol, 2008,7（2）:143⁃148. doi: 10.1111/j.1473⁃2165.2008.00379.x.
［22］	Lee E, Min K, Ahn H, et al. Potential therapeutic skin microbiomes suppressing Staphylococcus aureus⁃derived immune responses and upregulating skin barrier function⁃related genes via the AhR signaling pathway［J］. Int J Mol Sci, 2022,23（17）:9551. doi: 10.3390/ijms23179551.
［23］	Munera⁃Campos M, Ballesca F, Richarz N, et al. Paradoxical eczematous reaction to ixekizumab［J］. J Eur Acad Dermatol Venereol, 2019,33（1）:e40⁃e42. doi: 10.1111/jdv.15156.
［24］	Kimura R, Sugita K, Yamamoto O. Successful switching to brodalumab in a patient with severe psoriasis developing ixekizumab⁃induced eczema［J］. Eur J Dermatol, 2020,30（6）:732⁃734. doi: 10.1684/ejd.2020.3904.
［25］	Caldarola G, Pirro F, Di Stefani A, et al. Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL⁃17 treatment: a case series and review of the literature［J］. Expert Opin Biol Ther, 2020,20（6）:665⁃672. doi: 10.1080/14712598.2020.1727439.
［26］	Danset M, Hacard F, Jaulent C, et al. Brodalumab⁃associated generalized eczematous eruption in a difficult⁃to⁃treat psoriasis patient: management without brodalumab withdrawal［J］. Eur J Dermatol, 2020,30（6）:741⁃743. doi: 10.1684/ejd.2020.3910.
［27］	李妍, 李明, 李邻峰. 湿疹样损害与银屑病样损害的免疫漂移［J］. 皮肤科学通报, 2023,40（1）:37⁃43.
［28］	Ishiuji Y, Umezawa Y, Asahina A, et al. Exacerbation of atopic dermatitis symptoms by ustekinumab in psoriatic patients with elevated serum immunoglobulin E levels: report of two cases［J］. J Dermatol, 2018,45（6）:732⁃734. doi: 10.1111/1346⁃8138. 14295.
［29］	Nakajima K, Abe T, Saji R, et al. Atopic dermatitis exacerbated with ustekinumab in a psoriatic patient with childhood history of atopy［J］. Allergol Int, 2020,64（4）:382⁃383. doi: 10.1016/j.jinf. 2020.08.021.
［30］	Hattori N, Koike Y, Murota H. Treatment with an interleukin⁃17 inhibitor resulted in complete remission of psoriasis and flare⁃up of atopic dermatitis［J］. J Dermatol, 2022,49（5）:e173⁃e174. doi: 10.1111/1346⁃8138.16308.
［31］	Burlando M, Cozzani E, Russo R, et al. Atopic⁃like dermatitis after secukinumab injection: a case report［J］. Dermatol Ther, 2019,32（1）:e12751. doi: 10.1111/dth.12751.
［32］	Koschitzky M, Tan K, Noliza Encarnacion MR, et al. Eczematous reactions to psoriasis biologics treated with dupilumab: a case series［J］. JAAD Case Rep, 2021,11:29⁃32. doi: 10.1016/j.jdcr. 2021.03.006.
［33］	Mendes Roncada EV, Brambilla VR, Freitas Filitto B, et al. Atopic dermatitis as a paradoxical effect of secukinumab for the treatment of psoriasis［J］. Case Rep Dermatol, 2021,13（2）:336⁃339. doi: 10.1159/000513467.
［34］	Paolino G, Di Nicola MR, Brianti P, et al. New onset atopic dermatitis and psoriasis in the same patients under biologic treatments: the role of systemic treatments as a possible trigger［J］. Dermatol Ther, 2022,35（11）:e15814. doi: 10.1111/dth.15814.
［35］	Bose R, Beecker J. Dyshidrotic eczema in two patients on secukinumab for plaque psoriasis: a case report［J］. SAGE Open Med Case Rep, 2020,8:2050313X20904561. doi: 10.1177/2050313X20904561.
［36］	Johnson MC, Bowers NL, Strowd LC. Concurrent atopic dermatitis and psoriasis vulgaris: implications for targeted biologic therapy［J］. Cutis, 2022,109（2）:110⁃112. doi: 10.12788/cutis.0453.
［37］	Fowler E, Silverberg JI, Fox JD, et al. Psoriasiform dermatitis after initiation of treatment with dupilumab for atopic dermatitis［J］. Dermatitis, 2019,30（3）:234⁃236. doi: 10.1097/DER.0000 000000000481.
［38］	Ferrucci S, Tavecchio S, Berti E, et al. Acute onset of psoriasis in a patient with atopic dermatitis treated with dupilumab［J］. Clin Exp Dermatol, 2020,45（5）:625⁃626. doi: 10.1111/ced.14207.
［39］	D′Ambra I, Babino G, Fulgione E, et al. Psoriasis onset under dupilumab treatment in two patients affected by atopic dermatitis and one patient affected by alopecia areata: clinical and dermoscopic patterns［J］. Dermatol Ther, 2020,33（6）:e14169. doi: 10.1111/dth.14169.
［40］	Parker JJ, Sugarman JL, Silverberg NB, et al. Psoriasiform dermatitis during dupilumab treatment for moderate⁃to⁃severe atopic dermatitis in children［J］. Pediatr Dermatol, 2021,38（6）:1500⁃1505. doi: 10.1111/pde.14820.
［41］	Maiolini VM, Sousa NA, Marsillac PF, et al. Alopecia areata⁃like and psoriasis after dupilumab use for atopic dermatitis［J］. An Bras Dermatol, 2021,96（5）:634⁃636. doi: 10.1016/j.abd.2021. 03.005.
［42］	Mirza FN, Wang A, Ramachandran SM, et al. Dupilumab⁃induced phenotype switch from atopic dermatitis to psoriasis is characterized by de novo interleukin⁃17A expression: a case report［J］. Br J Dermatol, 2021,185（2）:432⁃434. doi: 10.1111/bjd.20064.
［43］	Jia X, Li C, Wu J, et al. Pustular psoriasis aappearing induced by dupilumab therapy in a patient with atopic dermatitis［J］. J Drugs Dermatol, 2022,21（3）:311⁃312. doi: 10.36849/JDD.6271.
［44］	Zhong X, Li Y, Gao Y, et al. Pustular psoriasis appearing in a Chinese woman treated with dupilumab for atopic dermatitis: a case report［J］. Dermatol Ther, 2022,35（11）:e15851. doi: 10. 1111/dth.15851.
［45］	Fan J, Zhang L, Lu Y, et al. A case of dupilumab⁃induced reverse psoriasis in a patient with atopic dermatitis［J］. Dermatol Ther, 2022,35（4）:e15345. doi: 10.1111/dth.15345.

[1]	胡梦瑶李敏陈思涵魏雪翠陈宇杰徐松陈旭. 角质形成细胞表达的S100A8/A9在3种常见皮肤炎症损伤模式中调控效应差异的研究[J]. 中华皮肤科杂志, 2024, 57(5): 435-444.
[2]	中国医师协会皮肤科医师分会中国中西医结合学会皮肤性病学分会. 红皮病型银屑病诊疗中国专家共识（2024版）[J]. 中华皮肤科杂志, 2024, 57(5): 409-417.
[3]	陆佳维鲁严. 肿瘤坏死因子α抑制剂及其他生物制剂相关矛盾性银屑病的临床研究进展[J]. 中华皮肤科杂志, 2024, 57(5): 479-482.
[4]	张元文孙从乾潘文东. 肉毒毒素在皮肤科的超适应证临床应用[J]. 中华皮肤科杂志, 2024, 57(5): 471-475.
[5]	郭澜晋红中. 治疗瘙痒的小分子/生物制剂药物研究进展[J]. 中华皮肤科杂志, 2024, 57(5): 475-478.
[6]	丁瑞张卫亮李静陈羽佳李珺莹. 度普利尤单抗治疗5例难治性内源性角化型手足部湿疹[J]. 中华皮肤科杂志, 2024, 0(4): 20230429-e20230429.
[7]	赵迎高翠娥隋昕宋志强. 基于高加索人单细胞转录组的炎症性树突状表皮细胞的免疫代谢研究[J]. 中华皮肤科杂志, 2024, 57(4): 343-349.
[8]	严汝帆廖洁月郭子瑜姚南周文玉罗帅寒天张桂英赵明. 天疱疮发病机制和靶向治疗的研究进展[J]. 中华皮肤科杂志, 2024, 57(4): 374-378.
[9]	岳淑珍树叶罗鸯鸯李珂瑶张圆圆汤建萍韦祝. 奥马珠单抗治疗儿童慢性荨麻疹的疗效和安全性回顾研究[J]. 中华皮肤科杂志, 2024, 57(4): 354-358.
[10]	田静邓思思宋志强. 特应性与非特应性结节性痒疹患者临床特征比较[J]. 中华皮肤科杂志, 2024, 57(4): 331-337.
[11]	宗杨永怡马楚君苏忠兰. 银屑病生物制剂治疗后湿疹化发生机制及应对策略[J]. 中华皮肤科杂志, 2024, 0(3): 20220578-e20220578.
[12]	王煜坤刘洁. 深度学习在非肿瘤性皮肤病中的应用进展[J]. 中华皮肤科杂志, 2024, 0(3): 20220660-e20220660.
[13]	姚曼雪周乃慧. 程序性细胞死亡蛋白1/程序性细胞死亡蛋白配体1抑制剂相关的Stevens-Johnson综合征/中毒性表皮坏死松解症研究进展 [J]. 中华皮肤科杂志, 2024, 0(3): 20220644-e20220644.
[14]	李芳林颖. 头颈部特应性皮炎的诊疗研究进展[J]. 中华皮肤科杂志, 2024, 0(3): 20230562-e20230562.
[15]	袁立燕余晓玲王晓华杨斌. [开放获取] TYK2抑制剂治疗斑块状银屑病的作用机制和临床研究进展[J]. 中华皮肤科杂志, 2024, 0(3): 20220740-e0220740.

生物制剂在银屑病和特应性皮炎中的应用与免疫表型转换机制研究进展

Application of biological therapies and mechanisms of immunophenotypic switching in psoriasis and atopic dermatitis

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 45

相关文章 15

Metrics

本文评价

推荐阅读 10